StockMacro
Company, fund or insider

Help

Menu

Avita Medical

$15.62 +268% in 6 monthsMarket cap $495.0M

RCEL on XNAS, Health Care, Avita Medical, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 53% and the stock is up 307% in a year, but it lost $36.1M over 12 months.

  • BadFree cash flow was minus $19.3M over the last 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
226
Website
avitamedical.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $26.1M, net loss $6.2M.
Quarter to 31 Dec 2021: revenue $6.9M, net income -$8.5MQuarter to 31 Dec 2021: revenue $6.9M, net income -$8.5MQuarter to 31 Mar 2022: revenue $7.5M, net income -$9.5MQuarter to 31 Mar 2022: revenue $7.5M, net income -$9.5MQuarter to 30 Jun 2022: revenue $8.3M, net income -$6.3MQuarter to 30 Jun 2022: revenue $8.3M, net income -$6.3MQuarter to 30 Sep 2022: revenue $9.1M, net income -$5.6MQuarter to 30 Sep 2022: revenue $9.1M, net income -$5.6MQuarter to 31 Dec 2022: revenue $9.5M, net income -$5.4MQuarter to 31 Dec 2022: revenue $9.5M, net income -$5.4MQuarter to 31 Mar 2023: revenue $10.6M, net income -$9.2MQuarter to 31 Mar 2023: revenue $10.6M, net income -$9.2MQuarter to 30 Jun 2023: revenue $11.8M, net income -$10.4MQuarter to 30 Jun 2023: revenue $11.8M, net income -$10.4MQuarter to 30 Sep 2023: revenue $13.6M, net income -$8.7MQuarter to 30 Sep 2023: revenue $13.6M, net income -$8.7MQuarter to 31 Dec 2023: revenue $14.2M, net income -$7.1MQuarter to 31 Dec 2023: revenue $14.2M, net income -$7.1MQuarter to 31 Mar 2024: revenue $11.1M, net income -$18.7MQuarter to 31 Mar 2024: revenue $11.1M, net income -$18.7MQuarter to 30 Jun 2024: revenue $15.2M, net income -$15.4MQuarter to 30 Jun 2024: revenue $15.2M, net income -$15.4MQuarter to 30 Sep 2024: revenue $19.5M, net income -$16.2MQuarter to 30 Sep 2024: revenue $19.5M, net income -$16.2MQuarter to 31 Dec 2024: revenue $18.4M, net income -$11.6MQuarter to 31 Dec 2024: revenue $18.4M, net income -$11.6MQuarter to 31 Mar 2025: revenue $18.5M, net income -$13.9MQuarter to 31 Mar 2025: revenue $18.5M, net income -$13.9MQuarter to 30 Jun 2025: revenue $18.4M, net income -$9.9MQuarter to 30 Jun 2025: revenue $18.4M, net income -$9.9MQuarter to 30 Sep 2025: revenue $17.1M, net income -$13.2MQuarter to 30 Sep 2025: revenue $17.1M, net income -$13.2MQuarter to 31 Dec 2025: revenue $17.6M, net income -$11.6MQuarter to 31 Dec 2025: revenue $17.6M, net income -$11.6MQuarter to 31 Mar 2026: revenue $19.3M, net income -$10.6MQuarter to 31 Mar 2026: revenue $19.3M, net income -$10.6MQuarter to 30 Jun 2026: revenue $21.7M, net income -$7.7MQuarter to 30 Jun 2026: revenue $21.7M, net income -$7.7MQuarter to 30 Sep 2026: revenue $26.1M, net income -$6.2MQuarter to 30 Sep 2026: revenue $26.1M, net income -$6.2M
31 Dec 2021RevenueNet incomeNet losstallest bar $26.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$26.1M-$6.2M
30 Jun 2026$21.7M-$7.7M
31 Mar 2026$19.3M-$10.6M
31 Dec 2025$17.6M-$11.6M
30 Sep 2025$17.1M-$13.2M
30 Jun 2025$18.4M-$9.9M
31 Mar 2025$18.5M-$13.9M
31 Dec 2024$18.4M-$11.6M
30 Sep 2024$19.5M-$16.2M
30 Jun 2024$15.2M-$15.4M
31 Mar 2024$11.1M-$18.7M
31 Dec 2023$14.2M-$7.1M
30 Sep 2023$13.6M-$8.7M
30 Jun 2023$11.8M-$10.4M
31 Mar 2023$10.6M-$9.2M
31 Dec 2022$9.5M-$5.4M
30 Sep 2022$9.1M-$5.6M
30 Jun 2022$8.3M-$6.3M
31 Mar 2022$7.5M-$9.5M
31 Dec 2021$6.9M-$8.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $84.7M $72.4M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +17% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$36.1M -$48.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.17 -$1.81
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 82.4% 83.7% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -33.9% -58.1% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -42.7% -67.1% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$19.3M -$37.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $10.5M $23.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $45.5M $42.4M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $35.0M $19.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 5.8 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 6.2 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Avita MedicalRCEL (this company) $495.0Mloss5.8+17%-42.7%
CarlsmedCARL $477.4Mloss6.7+60%-55.8%
Orchestra BioMedOBIO $517.9Mloss16.6+1007%-183%
AngioDynamicsANGO $454.6Mloss1.4+8.2%-10.1%
MiMedxMDXG $445.1Mloss1.5-23%-6.3%
Sight SciencesSGHT $565.8Mloss6.4+16%-32.1%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+53%

$26.1M vs $17.1M (quarter ended 30 Sep 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+21%

88 13F filers vs 73

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

29%

9.3M shares held by 13F filers (30 Sep 2026) of 31.4M outstanding (3 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

8.9%

2.8M shares sold short (30 Oct 2026) of 31.4M outstanding (3 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.1

2.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-1.0%

2.8M shares sold short in the report before, 2.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

49%

49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 60%

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$13.3M

the 12 months before: $359K

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$30K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 3.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

2.3×

8 articles in the last 7 days; its usual week has 3.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Revenue $25.9M, 1.5× a year earlier

Price $15.62 on 20 Nov 2026, +307% over 12 months (12-month range $3.27 to $17.65)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $227K in the last 12 months (the 12 months before: $345K).
Revenue per quarter. Revenue $26.1M in the latest quarter, +53% on a year earlier.
Capital spending per quarter. Capital spending $111K in the latest quarter, -88% on a year earlier.
Institutional holders (13F filers). 88 13F filers reported holding it in the latest 13F quarter, +22% on a year earlier.
Federal obligations. Federal obligations: $13.2M published in the last 12 months, +3455% on the 12 months before.
Lobbying spend. Lobbying spend: $30K published in the last 12 months, +100% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
10 Nov 2026Sharp changeQuarterly revenue change: quarterly revenue change, 25.9M vs usual 18.3M (2026-09-30); 1.5x the same period a year earlier
3 Jun 20268-K and other filingsDirector or officer change
1 May 20268-K and other filingsDirector or officer change
1 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Apr 2026Lobbying filinglobbying engagement terminated (JEFFREY J. KIMBELL & ASSOCIATES, INC.)
13 Jan 20268-K and other filingsA major agreement ended
5 Jan 20268-K and other filingsDirector or officer change
20 Oct 2025Sharp changeLobbying on a new issue: lobbying on a new issue: MMM (2025-09-30)
16 Oct 20258-K and other filingsDirector or officer change
2 Sep 2025Sharp changeShort interest spike: short interest spike, 5.4M vs usual 1.8M (2025-08-15); 3.3x the same period a year earlier
12 Aug 2025Sharp changeShort interest spike: short interest spike, 5.8M vs usual 1.8M (2025-07-31); 3.1x the same period a year earlier
6 Aug 20258-K and other filingsDirector or officer change
29 Jul 2025Sharp changeShort interest spike: short interest spike, 5.7M vs usual 1.8M (2025-07-15); 2.9x the same period a year earlier
18 Jul 2025Lobbying filingnew lobbying registration (JEFFREY J. KIMBELL & ASSOCIATES, INC.)
1 Jul 2025Sharp changeShort interest spike: short interest spike, 4.5M vs usual 1.8M (2025-06-13); 2.2x the same period a year earlier
17 Jun 2025Sharp changeShort interest spike: short interest spike, 4.0M vs usual 1.8M (2025-05-30); 2.1x the same period a year earlier
4 Jun 20258-K and other filingsDirector or officer change
4 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Jun 2025Sharp changeShort interest spike: short interest spike, 3.7M vs usual 1.7M (2025-05-15); 2.2x the same period a year earlier
13 May 2025Sharp changeShort interest spike: short interest spike, 3.0M vs usual 1.6M (2025-04-30); 1.9x the same period a year earlier
21 Feb 2025Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 4 filing(s) in 30 days, value_usd total 127K)
2 Jul 2024Sharp changeShort interest spike: short interest spike, 2.0M vs usual 729K (2024-06-14); 3.6x the same period a year earlier
1 Jul 20248-K and other filingsDirector or officer change
18 Jun 2024Sharp changeShort interest spike: short interest spike, 1.9M vs usual 675K (2024-05-31); 3.8x the same period a year earlier
6 Jun 20248-K and other filingsDirector or officer change
6 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 May 2024Sharp changeShort interest spike: short interest spike, 1.7M vs usual 608K (2024-05-15); 3.6x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 1.6M vs usual 592K (2024-04-30); 2.9x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 1.2M vs usual 592K (2024-04-15); 1.7x the same period a year earlier
23 Oct 20238-K and other filingsDirector or officer change
23 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Aug 2023Sharp changeShort interest spike: short interest spike, 1.3M vs usual 348K (2023-07-14); 4.4x the same period a year earlier
18 Jul 2023Sharp changeShort interest spike: short interest spike, 1.2M vs usual 348K (2023-06-30); 2.9x the same period a year earlier
15 Jun 20238-K and other filingsDirector or officer change
7 Jun 20238-K and other filingsDirector or officer change
12 May 20238-K and other filingsDirector or officer change
27 Mar 20238-K and other filingsDirector or officer change
22 Mar 20238-K and other filingsDirector or officer change
21 Mar 20238-K and other filingsDirector or officer change
20 Jan 20238-K and other filingsDirector or officer change
20 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Sep 20228-K and other filingsDirector or officer change
30 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Apr 20228-K and other filingsDirector or officer change
21 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Feb 2022: -$94K published
Month from 1 Nov 2022: -$1.1M published
Month from 1 Jun 2023: $16K published
Month from 1 Aug 2023: $124K published
Month from 1 Sep 2023: -$66K published
Month from 1 Nov 2023: $71K published
Month from 1 Dec 2023: -$33K published
Month from 1 Feb 2024: $22K published
Month from 1 Jun 2024: $9K published
Month from 1 Dec 2024: $12K published
Month from 1 Jan 2025: $6K published
Month from 1 Feb 2025: $121K published
Month from 1 Mar 2025: $91K published
Month from 1 Aug 2025: $114K published
Month from 1 Feb 2026: $12K published
Month from 1 Mar 2026: $9K published
Month from 1 May 2026: $17K published
Month from 1 Jun 2026: $189K published
Revenue per quarter
Quarter ended 31 Dec 2021: $6.9M, +36% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $7.5M, -14% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $8.3M, -19% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $9.1M, +30% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $9.5M, +36% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $10.6M, +40% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $11.8M, +41% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $13.6M, +50% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $14.2M, +50% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $11.1M, +5.3% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $15.2M, +29% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $19.5M, +43% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $18.4M, +30% on a year earlier; public on 14 Feb 2025
Quarter ended 31 Mar 2025: $18.5M, +67% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $18.4M, +21% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $17.1M, -13% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $17.6M, -4.3% on a year earlier; public on 13 Feb 2026
Quarter ended 31 Mar 2026: $19.3M, +4.0% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $21.7M, +18% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $26.1M, +53% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2021: $326K, -3.0% on a year earlier; public on 13 May 2022
Quarter ended 31 Mar 2022: $64K, -80% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $214K, +80% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $104K, +55% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $70K; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $284K, +344% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $299K, +40% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $502K, +383% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $296K, +323% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $1.1M, +304% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $2.7M, +787% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $3.8M, +649% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $1.6M, +445% on a year earlier; public on 14 Feb 2025
Quarter ended 31 Mar 2025: $221K, -81% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $524K, -80% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $934K, -75% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $19K, -91% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $108K, -79% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $111K, -88% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 55; public on 14 Feb 2022
31 Mar 2022 report: 63; public on 16 May 2022
30 Jun 2022 report: 53; public on 15 Aug 2022
30 Sep 2022 report: 45; public on 14 Nov 2022
31 Dec 2022 report: 52; public on 14 Feb 2023
31 Mar 2023 report: 69; public on 15 May 2023
30 Jun 2023 report: 75; public on 14 Aug 2023
30 Sep 2023 report: 78; public on 14 Nov 2023
31 Dec 2023 report: 80; public on 14 Feb 2024
31 Mar 2024 report: 79; public on 15 May 2024
30 Jun 2024 report: 64; public on 14 Aug 2024
30 Sep 2024 report: 64; public on 14 Nov 2024
31 Dec 2024 report: 71; public on 14 Feb 2025
31 Mar 2025 report: 71; public on 15 May 2025
30 Jun 2025 report: 78; public on 14 Aug 2025
30 Sep 2025 report: 72; public on 14 Nov 2025
31 Dec 2025 report: 66; public on 17 Feb 2026
31 Mar 2026 report: 75; public on 15 May 2026
30 Jun 2026 report: 73; public on 14 Aug 2026
30 Sep 2026 report: 88; public on 16 Nov 2026
Federal obligations
Month from 1 Sep 2023: $41K published
Month from 1 Oct 2023: $28K published
Month from 1 Nov 2023: $0 published
Month from 1 Dec 2023: -$12.0M published
Month from 1 Jan 2024: $138K published
Month from 1 Feb 2024: $12.0M published
Month from 1 Aug 2024: $0 published
Month from 1 Nov 2024: $83K published
Month from 1 Jan 2025: $138K published
Month from 1 Apr 2025: $138K published
Month from 1 Jul 2025: $0 published
Month from 1 Nov 2025: $97K published
Month from 1 Feb 2026: -$12.5M published
Month from 1 Mar 2026: $138K published
Month from 1 Apr 2026: $25.5M published
Month from 1 Aug 2026: $0 published
Month from 1 Sep 2026: $138K published
Month from 1 Oct 2026: $0 published
Lobbying spend
Quarter from 1 Oct 2025: $15K published
Quarter from 1 Jan 2026: $15K published
Quarter from 1 Apr 2026: $15K published

What is unusual now

  • Made public in the last 90 days: it reported revenue of $25.9M for the quarter ended 30 Sep 2026, 1.5× the same quarter last year.
  • Quarterly revenue change: reported revenue of $25.9M for the quarter ended 30 Sep 2026, 1.5× the same quarter last year Public on 10 Nov 2026.
  • Insider net buying (open market): Insiders bought a net $227K in the last 12 months (the 12 months before: $345K).
  • Capital spending per quarter: Capital spending $111K in the latest quarter, -88% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 41 insider trades

No trades in the last 90 days; the latest was filed 10 Jun 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
10 Jun 2026Joseph Fralin WoodyDirectorBuy5,200$4.00$21KForm 4
9 Jun 2026Joseph Fralin WoodyDirectorBuy10,000$4.19$42KForm 4
5 Jun 2026Joseph Fralin WoodyDirectorBuy10,000$4.09$41KForm 4
3 Jun 2026Joseph Fralin WoodyDirectorBuy20,000$4.25$85KForm 4
20 May 2026David D O'TooleCFOBuy2,000$4.26$9KForm 4
19 May 2026David D O'TooleCFOBuy2,000$4.24$8KForm 4
11 Mar 2026David D O'TooleCFOBuy1,800$4.78$9KForm 4
23 Feb 2026David D O'TooleCFOBuy3,000$4.15$12KForm 4

88 institutions reported shares at the end of Q3 2026, 29% of the shares outstanding; 31 opened a position, 14 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Vanguard Capital Management LLC1.3M4.27%$15.7M+7,621+0.6%
Divisadero Street Capital Management, LP823K2.62%$9.7M+723K+723%
Marshall Wace, LLP701K2.23%$8.2M+362K+107%
BlackRock, Inc.560K1.78%$6.6M-5,429-1.0%
Two Sigma Investments, LP504K1.60%$5.9MNew+504K
Millennium Management LLC371K1.18%$4.3M+355K24 times as many
Parkman Healthcare Partners LLC351K1.12%$4.1MNew+351K
Geode Capital Management, LLC338K1.08%$4.0M-1,983-0.6%
Goldman Sachs Group Inc267K0.85%$3.1M+190K+247%
Walleye Capital LLC264K0.84%$3.1MNew+264K

Federal contracts

All 1 federal contracts

1 new award in 12 months, $25.5M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
9 Apr 2026Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$25.5MFDA-APPROVED AUTOGRAFT SPARING DEVICE FOR NATIONAL PREPAREDNESSUSAspending

Company events

All 42 company events

In 12 months: 3 director or officer changes, 3 major agreements, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
11 Aug 2026Signed a major agreement8-K
5 Jun 2026Signed a major agreement8-K
3 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
1 May 2026Director or officer change8-K
13 Jan 2026Signed a major agreement; A major agreement endedSame filing: took on new debt, sold shares privately8-K
5 Jan 2026Director or officer change8-K
6 Nov 2025Signed a major agreement8-K
16 Oct 2025Director or officer change8-K

Reported lobbying spend: $15K in Q1 2026, $15K in Q4 2025. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Mar 2026EndedJeffrey J. Kimbell & Associates, Inc.for Avita Medical, Inc.issues related to therapeutic wound care; issues related to reimbursement for wound care treatmentsHealth issues, Medicare/MedicaidFiling
9 Jul 2025NewJeffrey J. Kimbell & Associates, Inc.for Avita Medical, Inc.Issues related to reimbursement for autologous cell harvesting devices for wound careMedicare/Medicaid, Health issuesFiling
31 Dec 2017EndedFabiani & Companyfor Avita Medical, Inc.HealthcareHealth issues, DefenseFiling
5 Jan 2017NewFabiani & Companyfor Avita Medical, Inc.Business developmentHealth issues, MEDFiling

The 5 newest of 187 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

31 Aug 2021confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Avita Medical (RCEL): had 1.6M shares sold short in the 30 Jul 2021 report, 14× the same report last year, while it reported revenue of $10.3M for the quarter ended 30 Jun 2021, 2.7× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Short interest and volume: Short interest spike, became public on 11 Aug 2021
  • Financials: Quarterly revenue change, became public on 31 Aug 2021
2020-07-31: 119K2020-08-14: 141K2020-08-31: 196K2020-09-15: 122K2020-09-30: 253K2020-10-15: 237K2020-10-30: 265K2020-11-13: 268K2020-11-30: 256K2020-12-15: 255K2020-12-31: 495K2021-01-15: 479K2021-01-29: 470K2021-02-12: 417K2021-02-26: 391K2021-03-15: 408K2021-03-31: 823K2021-04-15: 802K2021-04-30: 787K2021-05-14: 884K2021-05-28: 848K2021-06-15: 749K2021-06-30: 1.5M2021-07-15: 1.6M2021-07-30: 1.6M
The 30 Jul 2021 report against the 24 reports before it. this reportearliernormal: 413K
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 11 Aug 2021

Avita Medical had 1.6M shares sold short in the 30 Jul 2021 report, 14× the same report last year.

This period
1.6M (the 30 Jul 2021 report)
Normal report (median of 24 earlier)
413K
Typical spread (median absolute deviation)
196K
How far from its usual level
+4.2
Same report last year
119K
History used
654 days
2020-07-31: 119K2020-08-14: 141K2020-08-31: 196K2020-09-15: 122K2020-09-30: 253K2020-10-15: 237K2020-10-30: 265K2020-11-13: 268K2020-11-30: 256K2020-12-15: 255K2020-12-31: 495K2021-01-15: 479K2021-01-29: 470K2021-02-12: 417K2021-02-26: 391K2021-03-15: 408K2021-03-31: 823K2021-04-15: 802K2021-04-30: 787K2021-05-14: 884K2021-05-28: 848K2021-06-15: 749K2021-06-30: 1.5M2021-07-15: 1.6M2021-07-30: 1.6M
the 30 Jul 2021 report24 earlier reportsnormal: 413K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 31 Aug 2021

Avita Medical reported revenue of $10.3M for the quarter ended 30 Jun 2021, 2.7× the same quarter last year.

This period
$10.3M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$3.9M
Typical spread (median absolute deviation)
$905K
How far from its usual level
+4.8
Same quarter last year
$3.9M
History used
1,004 days
2019-06-30: $2.5M2019-09-30: $3.2M2019-12-31: $3.3M2020-03-31: $3.9M2020-06-30: $3.9M2020-09-30: $5.1M2020-12-31: $5.1M2021-03-31: $8.8M2021-06-30: $10.3M
the quarter ended 30 Jun 20218 earlier quartersnormal: $3.9M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 10 Nov 2026Financials change

    reported revenue of $25.9M for the quarter ended 30 Sep 2026, 1.5× the same quarter last year.

    Same quarter last year: $16.9M; its normal quarter is $18.3M.

    See the evidence
    This period
    $25.9M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $18.3M
    Typical spread (median absolute deviation)
    $816K
    How far from its usual level
    +4.2
    Same quarter last year
    $16.9M
    History used
    2,922 days
    2024-09-30: $19.4M2024-12-31: $18.2M2025-03-31: $18.3M2025-06-30: $18.2M2025-09-30: $16.9M2025-12-31: $17.4M2026-03-31: $19.1M2026-06-30: $21.5M2026-09-30: $25.9M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $18.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 25 Aug 2026Insiders record

    O'Toole David D (CFO) bought 2,000 shares of RCEL ($7,940) [amended] (dated 24 Aug 2026)

  3. 11 Jun 2026Insiders record

    Woody Joseph Fralin (director) bought 5,200 shares of RCEL ($20,800) (dated 10 Jun 2026)

  4. 10 Jun 2026Insiders record

    Woody Joseph Fralin (director) bought 10,000 shares of RCEL ($41,900) (dated 9 Jun 2026)

  5. 6 Jun 2026Insiders record

    Woody Joseph Fralin (director) bought 10,000 shares of RCEL ($40,950) (dated 5 Jun 2026)

  6. 4 Jun 2026Insiders record

    Woody Joseph Fralin (director) bought 20,000 shares of RCEL ($84,950) (dated 3 Jun 2026)

  7. 3 Jun 2026Filings record

    Director or officer change

  8. 21 May 2026Insiders record

    O'Toole David D (CFO) bought 2,000 shares of RCEL ($8,520) (dated 20 May 2026)

  9. 20 May 2026Insiders record

    O'Toole David D (CFO) bought 2,000 shares of RCEL ($8,480) (dated 19 May 2026)

  10. 1 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 1 May 2026Filings record

    Director or officer change

  12. 15 Apr 2026Government contracts record

    AVITA MEDICAL AMERICAS, LLC: new Department of Health and Human Services contract 75A50126C00003 ($25.5M) (dated 9 Apr 2026)

  13. 3 Apr 2026Lobbying record

    AVITA MEDICAL, INC.: lobbying engagement terminated (JEFFREY J. KIMBELL & ASSOCIATES, INC.) (dated 31 Mar 2026)

  14. 12 Mar 2026Insiders record

    O'Toole David D (CFO) bought 1,800 shares of RCEL ($8,604) (dated 11 Mar 2026)

  15. 24 Feb 2026Insiders record

    O'Toole David D (CFO) bought 3,000 shares of RCEL ($12,450) (dated 23 Feb 2026)

  16. 13 Jan 2026Filings record

    A major agreement ended

  17. 5 Jan 2026Filings record

    Director or officer change

  18. 20 Oct 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MMM']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4690171
  19. 16 Oct 2025Filings record

    Director or officer change

  20. 30 Aug 2025Insiders record

    McNamara Robert (director) bought 10,000 shares of RCEL ($45,000) (dated 29 Aug 2025)

  21. 27 Aug 2025Short interest and volume change

    had 5.4M shares sold short in the 15 Aug 2025 report, 3.3× the same report last year.

    Same report last year: 1.6M; its normal report is 1.8M.

    See the evidence
    This period
    5.4M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    628K
    How far from its usual level
    +3.8
    Same report last year
    1.6M
    History used
    2,131 days
    2024-08-15: 1.6M2024-08-30: 1.5M2024-09-13: 1.6M2024-09-30: 1.5M2024-10-15: 1.3M2024-10-31: 1.2M2024-11-15: 1.0M2024-11-29: 1.2M2024-12-13: 1.2M2024-12-31: 1.5M2025-01-15: 1.8M2025-01-31: 1.8M2025-02-14: 1.9M2025-02-28: 1.7M2025-03-14: 2.3M2025-03-31: 2.5M2025-04-15: 2.8M2025-04-30: 3.0M2025-05-15: 3.7M2025-05-30: 4.0M2025-06-13: 4.5M2025-06-30: 5.5M2025-07-15: 5.7M2025-07-31: 5.8M2025-08-15: 5.4M
    the 15 Aug 2025 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 27 Aug 2025Insiders record

    O'Toole David D (CFO) bought 2,000 shares of RCEL ($9,040) (dated 26 Aug 2025)

  23. 21 Aug 2025Insiders record

    McNamara Robert (director) bought 10,000 shares of RCEL ($50,000) (dated 20 Aug 2025)

  24. 13 Aug 2025Insiders record

    O'Toole David D (CFO) bought 2,000 shares of RCEL ($9,620) (dated 12 Aug 2025)

  25. 12 Aug 2025Short interest and volume change

    had 5.8M shares sold short in the 31 Jul 2025 report, 3.1× the same report last year.

    Same report last year: 1.9M; its normal report is 1.8M.

    See the evidence
    This period
    5.8M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    577K
    How far from its usual level
    +4.7
    Same report last year
    1.9M
    History used
    2,116 days
    2024-07-31: 1.9M2024-08-15: 1.6M2024-08-30: 1.5M2024-09-13: 1.6M2024-09-30: 1.5M2024-10-15: 1.3M2024-10-31: 1.2M2024-11-15: 1.0M2024-11-29: 1.2M2024-12-13: 1.2M2024-12-31: 1.5M2025-01-15: 1.8M2025-01-31: 1.8M2025-02-14: 1.9M2025-02-28: 1.7M2025-03-14: 2.3M2025-03-31: 2.5M2025-04-15: 2.8M2025-04-30: 3.0M2025-05-15: 3.7M2025-05-30: 4.0M2025-06-13: 4.5M2025-06-30: 5.5M2025-07-15: 5.7M2025-07-31: 5.8M
    the 31 Jul 2025 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 6 Aug 2025Filings record

    Director or officer change

  27. 25 Jul 2025Short interest and volume change

    had 5.7M shares sold short in the 15 Jul 2025 report, 2.9× the same report last year.

    Same report last year: 2.0M; its normal report is 1.8M.

    See the evidence
    This period
    5.7M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    507K
    How far from its usual level
    +5.2
    Same report last year
    2.0M
    History used
    2,100 days
    2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.6M2024-08-30: 1.5M2024-09-13: 1.6M2024-09-30: 1.5M2024-10-15: 1.3M2024-10-31: 1.2M2024-11-15: 1.0M2024-11-29: 1.2M2024-12-13: 1.2M2024-12-31: 1.5M2025-01-15: 1.8M2025-01-31: 1.8M2025-02-14: 1.9M2025-02-28: 1.7M2025-03-14: 2.3M2025-03-31: 2.5M2025-04-15: 2.8M2025-04-30: 3.0M2025-05-15: 3.7M2025-05-30: 4.0M2025-06-13: 4.5M2025-06-30: 5.5M2025-07-15: 5.7M
    the 15 Jul 2025 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 18 Jul 2025Lobbying record

    AVITA MEDICAL, INC.: new lobbying registration (JEFFREY J. KIMBELL & ASSOCIATES, INC.) (dated 9 Jul 2025)

  29. 26 Jun 2025Short interest and volume change

    had 4.5M shares sold short in the 13 Jun 2025 report, 2.2× the same report last year.

    Same report last year: 2.0M; its normal report is 1.8M.

    See the evidence
    This period
    4.5M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    310K
    How far from its usual level
    +5.9
    Same report last year
    2.0M
    History used
    2,068 days
    2024-06-14: 2.0M2024-06-28: 1.6M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.6M2024-08-30: 1.5M2024-09-13: 1.6M2024-09-30: 1.5M2024-10-15: 1.3M2024-10-31: 1.2M2024-11-15: 1.0M2024-11-29: 1.2M2024-12-13: 1.2M2024-12-31: 1.5M2025-01-15: 1.8M2025-01-31: 1.8M2025-02-14: 1.9M2025-02-28: 1.7M2025-03-14: 2.3M2025-03-31: 2.5M2025-04-15: 2.8M2025-04-30: 3.0M2025-05-15: 3.7M2025-05-30: 4.0M2025-06-13: 4.5M
    the 13 Jun 2025 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 11 Jun 2025Short interest and volume change

    had 4.0M shares sold short in the 30 May 2025 report, 2.1× the same report last year.

    Same report last year: 1.9M; its normal report is 1.8M.

    See the evidence
    This period
    4.0M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    296K
    How far from its usual level
    +5.0
    Same report last year
    1.9M
    History used
    2,054 days
    2024-05-31: 1.9M2024-06-14: 2.0M2024-06-28: 1.6M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.6M2024-08-30: 1.5M2024-09-13: 1.6M2024-09-30: 1.5M2024-10-15: 1.3M2024-10-31: 1.2M2024-11-15: 1.0M2024-11-29: 1.2M2024-12-13: 1.2M2024-12-31: 1.5M2025-01-15: 1.8M2025-01-31: 1.8M2025-02-14: 1.9M2025-02-28: 1.7M2025-03-14: 2.3M2025-03-31: 2.5M2025-04-15: 2.8M2025-04-30: 3.0M2025-05-15: 3.7M2025-05-30: 4.0M
    the 30 May 2025 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 4 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 4 Jun 2025Filings record

    Director or officer change

  33. 28 May 2025Short interest and volume change

    had 3.7M shares sold short in the 15 May 2025 report, 2.2× the same report last year.

    Same report last year: 1.7M; its normal report is 1.7M.

    See the evidence
    This period
    3.7M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    242K
    How far from its usual level
    +5.5
    Same report last year
    1.7M
    History used
    2,039 days
    2024-05-15: 1.7M2024-05-31: 1.9M2024-06-14: 2.0M2024-06-28: 1.6M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.6M2024-08-30: 1.5M2024-09-13: 1.6M2024-09-30: 1.5M2024-10-15: 1.3M2024-10-31: 1.2M2024-11-15: 1.0M2024-11-29: 1.2M2024-12-13: 1.2M2024-12-31: 1.5M2025-01-15: 1.8M2025-01-31: 1.8M2025-02-14: 1.9M2025-02-28: 1.7M2025-03-14: 2.3M2025-03-31: 2.5M2025-04-15: 2.8M2025-04-30: 3.0M2025-05-15: 3.7M
    the 15 May 2025 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 10 May 2025Short interest and volume change

    had 3.0M shares sold short in the 30 Apr 2025 report, 1.9× the same report last year.

    Same report last year: 1.6M; its normal report is 1.6M.

    See the evidence
    This period
    3.0M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    232K
    How far from its usual level
    +3.9
    Same report last year
    1.6M
    History used
    2,024 days
    2024-04-30: 1.6M2024-05-15: 1.7M2024-05-31: 1.9M2024-06-14: 2.0M2024-06-28: 1.6M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.6M2024-08-30: 1.5M2024-09-13: 1.6M2024-09-30: 1.5M2024-10-15: 1.3M2024-10-31: 1.2M2024-11-15: 1.0M2024-11-29: 1.2M2024-12-13: 1.2M2024-12-31: 1.5M2025-01-15: 1.8M2025-01-31: 1.8M2025-02-14: 1.9M2025-02-28: 1.7M2025-03-14: 2.3M2025-03-31: 2.5M2025-04-15: 2.8M2025-04-30: 3.0M
    the 30 Apr 2025 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 11 Mar 2025Insiders record

    McNamara Robert (director) bought 11,000 shares of RCEL ($91,300) (dated 10 Mar 2025)

  36. 21 Feb 2025Insiders change

    had 3 insiders buy $127K of its shares on the open market within 30 days (4 filings).

    Who bought: Crowe Suzanne, O'Toole David D, McNamara Robert.

    See the evidence (4 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    4
    Total bought
    $127K
    Window
    22 Jan 2025 to 21 Feb 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  37. 21 Feb 2025Insiders record

    O'Toole David D (CFO) bought 1,000 shares of RCEL ($9,900) (dated 20 Feb 2025)

  38. 21 Feb 2025Insiders record

    McNamara Robert (director) bought 10,000 shares of RCEL ($100,900) (dated 20 Feb 2025)

  39. 20 Feb 2025Insiders record

    O'Toole David D (CFO) bought 1,000 shares of RCEL ($10,250) (dated 19 Feb 2025)

  40. 30 Jan 2025Insiders record

    Crowe Suzanne (director) bought 486 shares of RCEL ($6,391) (dated 29 Jan 2025)

Showing the newest 40 of 95 entries; narrow the window or the kind of data to see older ones.

Not listed: 124 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001762303
Ticker
RCEL
Domain
avitamedical.com
Hq location
CA|VALENCIA|91355 (1 unverified)
Lobbying client
avita medical
Name
AVITA Medical Americas, LLC, Avita Medical, Inc., Avita Therapeutics, Inc.
Uei
JY1HRCEKX2L4, T3NUKR3AAX45, YKFASYUPNGZ2
Wikidata
Q4828994
Wikipedia
Avita Medical
  • Federal lobbying disclosures (LDA)4 records, 23 data points5 Jan 2017 to 31 Mar 2026
  • SEC Form 13F institutional holdings338 data points30 Sep 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)142 records19 Dec 2018 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)611 data points30 Jun 2017 to 3 Nov 2026
  • SEC Form 4 insider transactions41 records, 152 data points21 Jul 2020 to 24 Aug 2026
  • FINRA short interest (twice monthly)507 data points15 Oct 2019 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3588 data points1 Oct 2019 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 69 data points20 Jun 2023 to 9 Jul 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026